|
| Disorder | Physiopathological approach | Radioligand | Population | Therapeutical class | Main findings | References |
|
| AD | Amyloid | 18F-florbetapir | 12 month study to determine long-term effects of monthly SC injections on 146 amyloid positive patients with mild to moderate AD (36 placebo versus 110 bapineuzumab 2 mg, 7 mg, 20 mg) | Bapineuzumab immunotherapy | Bapineuzumab did not demonstrate significant difference over placebo on GCA of 5 SUVR ROI: anterior cingulate, frontal cortex, lateral temporal cortex, parietal cortex, posterior cingulate/precuneus). | Brody et al. [26] |
| Subgroup analysis based on disease severity: change in SUVR significant only in 7 mg/month group in patient with mild AD. |
| Amyloid | 11C-PiB | 78 weeks study on 28 patients with mild to moderate AD (8 placebo versus 20 Bapineuzumab IV 0.5 mg/kg, 10 mg/kg, 2.0 mg/kg) | Bapineuzumab immunotherapy | Estimated difference on cerebral retention ratio is significant between Bapineuzumab and placebo group. | Rinne et al. [25] |
| (7 placebo and 19 bapineuzumab included in PiB PET analysis) | ¹¹C-PiB PET seems to be useful in assessing the effects of potential AD treatments on cortical fibrillar amyloid-β load in vivo. |
| Amyloid | 11C-PiB | Patients with mild to moderate AD | Bapineuzumab immunotherapy | Change from baseline to week 78 for GCA SUVR was not statistically significant versus placebo in either study. | Vandenberghe et al. [27] |
| 2 substudies: ApoEε4 carriers (24 placebo versus 32 bapineuzumab IV 0.5 mg/kg) ApoEε4 non carriers (13 placebo versus 17 bapineuzumab IV 0,5 mg/kg) | No significant treatment differences were seen in amyloid burden on PiB-PET. |
| Amyloid | 11C-PiB | Patients with mild to moderate AD | Bapineuzumab immunotherapy | Significant differences in mean SUVR were only observed between bapineuzumab and placebo in the ApoE ε4 carrier study. | Salloway et al. [28] |
| PiB PET substudy: ApoE ε4 carriers: 75 Bapineuzumab IV versus 40 placebo; ApoE ε4 non-carriers: 22 Bapineuzumab IV versus 15 placebo |
| Amyloid | 18F-florbetapir | Patients with mild-to-moderate AD receiving placebo or solanezumab IV 4 weeks for 18 months | Solanezumab immunotherapy | The composite SUVR for the anterior and posterior right and left cingulate, plus right and left frontal, lateral temporal, and parietal regions, combined and normalized to the whole cerebellum, did no change significantly in the solanezumab group or the placebo group in either study. | Doody et al. [29] |
| Combining the 2 substudies, a total of 266 patients underwent PET examination at baseline and week 80 or early termination |
|
